TEPEZZA® (Teprotumumab-Trbw) Now Available at Premier Pharmacy Services
For the first time, TED patients have a medicine that has been shown to significantly improve eye bulging and double vision, among other painful and debilitating symptoms
BALDWIN PARK, Calif., April 5, 2021 (Newswire.com) - TEPEZZA® (teprotumumab-trbw), the first and only medicine approved by the U.S. Food and Drug Administration (FDA) to treat Thyroid Eye Disease (TED), is now available for eligible patients at Premier Pharmacy Services. TED is a rare autoimmune disease that causes painful and vision-threatening symptoms such as eye-bulging, double vision and changes in appearance. TED is most often seen in patients with Graves' disease, but it is a distinct disease that requires separate treatment.
Patients who are living with TED can contact Premier Pharmacy Services to learn more about whether TEPEZZA may be an option for them. Horizon Therapeutics, the maker of TEPEZZA, also offers Nurse Advocates who patients can call at 1-833-483-7399 to discuss TED, treatment with TEPEZZA and financial support that Horizon provides to help eligible patients.
TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). TEPEZZA is an IV (intravenous) treatment given once every three weeks for a total of eight infusions. This means it is delivered through a needle that is placed in the patient's arm. The FDA approval of TEPEZZA fulfills a serious unmet need for patients living with this debilitating disease who previously had no other approved treatment options.
A key study that led to the FDA approval of TEPEZZA found that significantly more patients treated with TEPEZZA had a meaningful improvement in eye bulging and double vision compared to placebo. The study also demonstrated improvements in other signs and symptoms of TED, including eye pain, redness and swelling. The majority of adverse events experienced with TEPEZZA were graded as mild to moderate and were manageable in the trials, with few discontinuations or therapy interruptions.
About Premier Pharmacy Services
Premier Pharmacy Services is headquartered in Baldwin Park, California, and is the largest independent specialty pharmacy, with satellite locations in Arizona, Missouri, Pennsylvania, and New Jersey. Premier's mission is to enable patients to successfully live with complex conditions by focusing on being an active partner throughout the entire patient journey with integrity compassion and excellence. The company offers customized clinical management programs nationwide through its proprietary software system, utilizing strategies that promote optimal outcomes for persons enduring debilitating diseases while delivering industry-leading patient care with integrity, compassion, and excellence. Premier Pharmacy works around the clock to provide patient-centric support and care.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.
For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.
Source: Premier Pharmacy Services